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Association (ADA) guidelines were simulated. Cost of treatment and complications
were based on officially published sources for medicines prices (www.mh.govern-
ment.bg), for hospital charges (www.nhif.bg) and verified by expert opinion survey
(1 BGN 0.51 EUR). Future costs were discounted with 5%. RESULTS: Treatment to
targets postpones minor complications by up to 4 years, delays major complica-
tions by 3 to 4 years and extends life expectancy from diagnosis by 3 years com-
pared with the baseline scenario. Total discounted cost savings over remaining life
expectancy from the diagnosis were from 2483 BGN to 2908 BGN per person.
CONCLUSIONS: Enhanced treatment leads to avoidance or delay of the complica-
tions of diabetes. This significantly reduces the impact diabetes can have on pa-
tients’ quality of life, life expectancy and cost of diabetes treatment in Bulgarian
health care system settings.
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BACKGROUND: Under the data of Russian Federal State Registry 2010 there are
around 3 million patients in diabetes. Also data of epidemiology assessment in the
frame of national project Health demonstrates that estimated number of patients
consists of 5-7% from total population that is 4 times higher. Death rate of cardio-
vascular complications is 1.5 thousand people per year. Every second patient gets
invalidity. So total expenditures for complications treatment tens times more than
costs on medical products and control devices. OBJECTIVES: 1) Provide local costs
of the disease, and 2) Assess benefits of new technology treatment versus tradi-
tional therapy.METHODS: Retrospective analysis of case studies of patients in D2T
from 4 regions of Russia. Average age - 61 years, duration of D2T - 7.5 years, body
mass index - more than 32 kg/m3, Hb1Ac - 8.1%. Isolation of two groups of patients:
1 - treated with adding of vildagliptin (n264); 2 - treated by traditional OAD with
sulfonylurea (n600). Comparative analysis Cost of Illness of two groups, and
correlation between antidiabetic medical products and risk of fatal complications.
RESULTS: Average cost of antidiabetic medical treatment of group 1 versus 2 is
more than 2 times expensive, 16,600 rub versus 7,000 rub per patient rep year.
Exchange rate is $1  30 rub. But total costs for the treatment of patients group 2
versus 1 is 30% higher (26,000 rub and 18,000 rub per patient per year accordingly).
The main reason - more number of vital important cardiovascular events and
exacerbations of hypertension and heart disease in group 2. Part of direct medical
costs for the treatment without antidiabetic products is 7% and 73% from total
costs for groups 1 and 2 accordingly. CONCLUSIONS: Usage of new antidiabetic
products - vildagliptin is a way to control of diabetes, development of cardiovas-
cular complications and total budget for the disease.
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OBJECTIVES: The prevalence of diabetes continues to grow, and it is estimated that
in Croatia we have 315.900 adults with diabetes (9.2% adult population), although in
many patients the disease has not yet been diagnosed. Majority of patients - 92,8%
suffers from diabetes mellitus type 2. The objectives of this study are to quantify
the economic burden of illness caused by increased health resource use and to
provide detailed breakdown of the costs attributed to diabetes. METHODS: Preva-
lence-based cost-of-illness methodology was used to estimate the direct costs
(hospital care, drugs, physician care, institutional care, additional costs) and indi-
rect costs (sickness leave) associated with micro and macro vascular complica-
tions, diabetes monitoring and drugs analyzed by types of diabetes complication
and health resource categories. RESULTS: Total cost of diabetes mellitus type 2 in
Croatia sums to 11,49% of national insurer‘s budget, i.e. 351,7 mil EUR in 2009.
Direct medical costs include 50,2 mil EUR to directly treat and monitor diabetes,
and 301,5 mil EUR to treat diabetes-related chronic complications. Diabetes medi-
cations make 8,75% of total illness cost. The largest components of medical expen-
ditures are hospital inpatient care (36,75%) and prescriptions for treating compli-
cations (28,49%). Hypertension and cardiopathy incur largest amount of
expenditures related to diabetes complications (76,2 mil EUR), followed by acute
myocardial infarction (68,6 mil EUR) and peripheral vascular disease (52 mil EUR).
Indirect costs equal 4,6 mil EUR. CONCLUSIONS: An average expenditure per per-
son with diagnosed diabetes type 2 in Croatia is 1.956 EUR yearly. These cost data
provide additional rationale for better disease monitoring and complication pre-
vention.
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OBJECTIVES: Diabetes mellitus (DM) is a major health problem with severe com-
plications and a significant impact on quality of life. It constitutes an enormous
burden of disease due to high prevalence, severe co-morbidities and high costs for
society. This study is the first comprehensive study on direct and indirect cost of
DM (type 1 and type 2) and its complications in Poland. METHODS: In order to
estimate the direct medical costs of DM and its complications, including the costs
of medical consultation, hospitalization, rehabilitation, drugs and medical equip-
ment data for the years 2004-2009 of the National Health Fund were used. Indirect
costs like costs of pensions for incapacity for work, the costs of rehabilitation and
loss of productivity due to diabetes and its complications were obtained from the
Department of Social Security for the years 2004-2009. RESULTS: Direct medical
costs of DM in Poland increased in the analysed period. The significant share of
these costs constitutes the costs of drugs (25.7% increase 2005 vs. 2007). Direct costs
of DM treatment, without costs of drugs, increased in the analysed period at similar
rate (type 1 – 22,7%, type 2 – 22,1%). The highest costs are associated with treatment
of diabetes complications. The total cost of treatment of DM showed in the anal-
ysed period an upward trend. The indirect costs are mainly determined by loss of
productivity, cost of pensions for incapacity for work and cost of rehabilitation. The
number of diabetic patients receiving pensions for incapacity for work is declining,
but this trend is being seen in the whole disability pensions system in Poland.
CONCLUSIONS: From year to year DM causes a growing economic burden on the
health care and to the Polish society in terms of health care and productivity loses.
PDB33
COST OF DIABETES MANAGEMENT TO COCOA CLINICS IN GHANA
Quaye EA1, Akweongo P2, Aikins MK2
1Medical Department, Ghana Cocoa Board, Accra, Gt. Accra, Ghana, 2University of Ghana, Legon,
Accra, Ghana
OBJECTIVES: To determine the financial cost of diabetes management to Cocoa
clinics for 2009. METHODS: A descriptive cross-sectional study of diabetes man-
agement at the four Cocoa clinics in Ghana from May to July 2010 was conducted.
The prevalence-based ‘Cost-of-illness’ approach from the institutional perspective
was employed. A pre-tested data extraction form was used to review the medical
records of 304 diabetes patients randomly selected. RESULTS: The mean age was
55.4 years. The annual financial cost of managing one diabetes patient was esti-
mated to be GH¢ 541.35 (US$ 373.34). Service cost constituted 22% whiles direct
medical cost was 78%. Drug cost was 71% of the financial cost. The cost of hospi-
talization per patient-day at Cocoa clinic was estimated at GHø 32.78 (US$ 22.61).
The total financial cost of Diabetes management was estimated at GH¢ 420,087.67
(US$ 289,715.63). This accounted for 8% of the total expenditure for the Clinics in
year 2009. The study showed that facility type, type of diabetes and presence of
complications is associated with the cost of Diabetes management to Cocoa clinics.
CONCLUSIONS: The cost of managing Diabetes Mellitus and accompanying com-
plications can be used to forecast the economic burden of the disease to the clinics.
The mean age indicates delay in diagnosing diabetes and accompanying compli-
cation which has cost implications. This calls for policies that will help in the early
detection in clinical practice and effective management protocols by Cocoa clinics.
Keywords: Diabetes, financial cost, Cocoa clinics, complication, Cost-of-illness,
Ghana.
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OBJECTIVES: To estimate annual treatment costs attributable to obesity (TC-ATO)
in diabetes patients in the US. METHODS: The study used Medical Expenditure
Panel Survey data from 2001-2008, a nationally representative sample of US non-
institutionalized population. Diabetic patients(18 years old) were identified using
ICD-9-CM code 250, clinical classification codes 049 and 050, or physician reported
diagnosis. Patients were classified as normal (body mass index(BMI)18.5-25 kg/
m2), overweight (BMI 25-30 kg/m2), or obese (BMI30 kg/m2). Patients with preg-
nancy, malignancy, kidney dialysis, immunodeficiency, or low BMI18.5 kg/m2
were excluded. Treatment costs included all costs for treating diabetic patients,
excluding dental health and injury costs. Adjusted costs were calculated using
generalized linear model(GLM) with log link function and gamma distribution. TC-
ATOs were estimated using recycled prediction and quantile regression method.
The recycled prediction method predicted costs for obese patients by calculating
costs using estimated coefficients from normal patients using GLM after adjusting
for the study variables. TC-ATO was the differences between actual costs and
predicted costs in the obese patients. In quantile regression, TC-ATO for each
quantile was estimated as the coefficient of the obese patients. All costs were
converted to 2010 US dollars using price indices. RESULTS: The average treatment
costs were $9,196 (95%CI:$8,213-$10,178) and $9,614 (95%CI:$9,124-$10,104) for nor-
mal and obese patients, respectively. The treatment costs in obese patients were
12% higher than those in normal patients after adjusting for other study vari-
ables(p0.029). Overall, the average TC-ATO in diabetic patients was predicted to
be $527(95%CI:$49-$1,005). TC-ATO calculated by quantile regression were
$154(95%CI:$68-240), $253(95%CI:$165-$342), $395(95%CI:$246-$545), $705(95%CI:
$395-$1,015) and $920($443-$1,397) for 10th, 25th, 50th, 75th, and 90th percentile,
respectively. CONCLUSIONS: Obese patients with diabetes have significantly
higher treatment costs compared to normal diabetic patients. The increased eco-
nomic burden attributable to obesity represents potentially avoidable costs, which
justifies allocating additional resources to therapeutic interventions aimed at re-
ducing weight.
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